SEPHIENCE Launch Drives Record Revenue for PTC Therapeutics; Director Resigns
PTCT sits 71% above its 52-week low of $43.175.
Summary
PTC Therapeutics reported record revenue, likely driven by its SEPHIENCE therapy, citing strong patient uptake and expanding market penetration. This positive operational update builds on the product revenue growth noted in the company's Q1 results reported on May 7th. Separately, director Alethia Young resigned from the board effective June 8, 2026, and will serve as a consultant for a year. The strong performance of SEPHIENCE is a key positive for the company's core business.
At the time of this announcement, PTCT was trading at $74.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $43.18 to $87.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.